Victoza (Liraglutide)

Overview

Victoza is a prescription injectable medication containing liraglutide, a GLP-1 receptor agonist developed and manufactured by Novo Nordisk. Approved by the FDA in January 2010, Victoza was one of the earliest GLP-1 receptor agonists to reach the market and has since become one of the most extensively studied diabetes medications in the world, with over a decade of real-world clinical experience.

Victoza is specifically indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Notably, in 2017 the FDA expanded Victoza's indication to include the reduction of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease, making it one of the few diabetes medications with a proven cardioprotective benefit.

While Victoza shares the same active ingredient as Saxenda (which is approved for weight management), Victoza is dosed at lower levels (maximum 1.8mg vs. 3.0mg) and is approved only for diabetes management. Patients seeking weight loss as a primary goal should discuss dedicated weight management medications with their healthcare provider.

How It Works

Victoza works by mimicking the action of the naturally occurring incretin hormone GLP-1 (glucagon-like peptide-1). When injected, liraglutide binds to GLP-1 receptors throughout the body, triggering several important physiological responses that help manage blood sugar levels in people with type 2 diabetes.

The primary mechanism involves glucose-dependent insulin secretion. When blood sugar levels are elevated (such as after a meal), Victoza stimulates the pancreas to release more insulin, helping to lower blood glucose. Critically, this effect is glucose-dependent, meaning the medication works more actively when blood sugar is high and less when it is normal, which significantly reduces the risk of hypoglycemia compared to some other diabetes medications like sulfonylureas.

Additionally, Victoza suppresses the release of glucagon (a hormone that raises blood sugar), slows gastric emptying to reduce post-meal glucose spikes, and acts on appetite centers in the brain to reduce food intake. These combined effects contribute to improved A1C levels and modest weight loss, which is a welcome benefit for many patients with type 2 diabetes who also struggle with excess weight.

Dosing Schedule

Victoza uses a straightforward dose-escalation schedule. Treatment begins with 0.6mg injected subcutaneously once daily for at least one week. This starting dose is intended for tolerability and is not effective for glycemic control on its own. After the first week, the dose is increased to 1.2mg daily, which is the standard therapeutic dose for most patients.

If additional glycemic control is needed after at least one week on the 1.2mg dose, the healthcare provider may increase the dose to 1.8mg daily. The injection can be given at any time of day, regardless of meals, in the abdomen, thigh, or upper arm. Patients should rotate injection sites within the same body region to reduce the risk of injection site reactions or lipodystrophy.

Victoza comes in a pre-filled, multi-dose pen that is designed for ease of use. Each pen delivers doses of 0.6mg, 1.2mg, or 1.8mg and should be stored in the refrigerator before first use. After initial use, the pen can be stored at room temperature (up to 86 degrees F) or in the refrigerator for up to 30 days. Needles are not included and must be purchased separately.

Effectiveness

Victoza has been studied extensively in the LEAD (Liraglutide Effect and Action in Diabetes) clinical trial program, which included over 6,500 patients across multiple studies. In these trials, Victoza demonstrated A1C reductions of approximately 1.0% to 1.5% from baseline, depending on the dose and whether it was used alone or in combination with other diabetes medications.

The landmark LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial, which followed over 9,300 patients for a median of 3.8 years, demonstrated that Victoza reduced the risk of major adverse cardiovascular events by 13% compared to placebo in patients with type 2 diabetes and high cardiovascular risk. This was a groundbreaking finding that established Victoza as a cardioprotective diabetes treatment.

In terms of weight effects, patients on Victoza typically experience modest weight loss of approximately 2 to 3 kg (5 to 7 pounds) over the course of treatment, which is less than what newer GLP-1 medications like Ozempic or Mounjaro provide. However, the combination of reliable blood sugar control, cardiovascular protection, and modest weight loss makes Victoza a well-rounded treatment option for many patients with type 2 diabetes.

Side Effects

Like other GLP-1 receptor agonists, the most common side effects of Victoza are gastrointestinal. Nausea is the most frequently reported adverse event, occurring in approximately 28% of patients in clinical trials. Other common GI side effects include diarrhea (17%), vomiting (11%), decreased appetite (10%), and constipation (10%). These side effects are generally mild to moderate and tend to improve within the first few weeks of treatment, particularly during the dose-escalation period.

Headache, dyspepsia (indigestion), and injection site reactions have also been reported. Hypoglycemia risk is low when Victoza is used alone but increases when combined with insulin or sulfonylureas; dose adjustments of these concomitant medications may be necessary. Some patients experience an increase in heart rate of 2 to 3 beats per minute on average, which should be monitored by their healthcare provider.

Rare but serious side effects include pancreatitis, gallbladder disease, renal impairment, and serious allergic reactions. Victoza carries the same boxed warning as other GLP-1 medications regarding thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, and should not be used during pregnancy.

Cost and Insurance

The retail price of Victoza without insurance is approximately $900 to $1,100 per month, depending on the pharmacy and prescribed dose. Each Victoza pen contains enough medication for varying durations depending on the dose: approximately 17 days at 0.6mg, 10 days at 1.2mg, and approximately 6 days at the 1.8mg dose. Patients on the 1.8mg dose typically need three pens per month.

Insurance coverage for Victoza is generally favorable for patients with type 2 diabetes, as it is a well-established medication with proven cardiovascular benefits. Most commercial insurance plans and Medicare Part D plans include Victoza on their formularies, though tier placement and copay amounts vary. Prior authorization may be required, and some plans may require documentation that patients have tried metformin first.

Novo Nordisk offers patient assistance programs and savings cards that can significantly reduce out-of-pocket costs. Eligible commercially insured patients may pay as little as $25 per month through the Novo Nordisk savings program. Patients without insurance or with high deductibles should explore these programs, as well as state pharmaceutical assistance programs and pharmacy discount cards, to help manage the cost of treatment.

Who Is Victoza For?

Victoza is indicated for adults with type 2 diabetes who need additional glycemic control beyond diet, exercise, and other oral medications. It is particularly well-suited for patients with established cardiovascular disease or high cardiovascular risk, as the LEADER trial demonstrated meaningful reductions in heart attack, stroke, and cardiovascular death. Patients who also want modest weight loss alongside blood sugar control may benefit from Victoza's appetite-reducing effects.

Victoza may be less ideal for patients who prefer weekly injections, as newer options like Ozempic and Trulicity offer once-weekly dosing with similar or superior efficacy. Patients primarily seeking weight loss rather than diabetes management should explore medications specifically approved for that purpose, such as Saxenda, Wegovy, or Zepbound.

As with all GLP-1 medications, the decision to start Victoza should involve a thorough discussion with a qualified healthcare provider. Your provider will consider your current A1C level, cardiovascular risk factors, other medications, insurance coverage, and personal preferences to determine whether Victoza is the most appropriate treatment option for your situation.